Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89Bio Inc (NQ: ETNB )

2.870 -0.250 (-8.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 231,871
Open 3.180
Bid (Size) 2.580 (2)
Ask (Size) 3.030 (3)
Prev. Close 3.120
Today's Range 2.750 - 3.330
52wk Range 2.000 - 22.31
Shares Outstanding 20,351,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Analyst Ratings for 89bio
89bio (NASDAQ:ETNB) has observed the following analyst ratings within the last quarter: 
Via Benzinga
10 Biggest Price Target Changes For Friday
Barclays cut the price target on Avis Budget Group, Inc. (NASDAQ: CAR) from $245 to $223. Avis Budget shares rose 2.3% to $224.98 in pre-market trading. 
Via Benzinga

Performance

YTD
-80.85%
-80.85%
1 Month
+7.49%
+7.49%
3 Month
-41.19%
-41.19%
6 Month
-81.03%
-81.03%
1 Year
-85.21%
-85.21%

More News

Read More
90 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Via Benzinga
Exposures COVID-19
10 Biggest Price Target Changes For Thursday
Via Benzinga
Recap: 89bio Q1 Earnings
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
73 Biggest Movers From Yesterday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
50 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
Via Benzinga
51 Biggest Movers From Yesterday
Via Benzinga
89bio's NASH Candidate Shows Improvement In Disease Severity, Cardiovascular Health
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2021
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.